European Stroke Prevention Study 2. Efficacy and safety data.
D000368:Aged; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control*; D003627:Data Interpretation, Statistical; D003692:Delayed-Action Preparations; D004176:Dipyridamole / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D010919:Placebos; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D012449:Safety
D003692:Delayed-Action Preparations; D010919:Placebos; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin